Evidence map›Paper›PMID 39902041›Full record

ArticleFrontiers in immunology2024

Špela Knez, Mojca Narat, Jernej Ogorevc

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Špela KnezDepartment of Animal Science, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia.
Mojca NaratDepartment of Animal Science, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia.
Jernej OgorevcDepartment of Animal Science, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Toll-like receptors (TLRs) play an important role in the recognition of viral particles and activation of the innate immune system, but their role in SARS-CoV-2 infection is still poorly characterized. In the present study, we investigated the role of Toll-like receptor 10 (TLR10) in modulating the immune response during SARS-CoV-2 infection. The results showed that overexpression of

Indexed as

Coronavirus Nucleocapsid ProteinsCOVID-19SARS-CoV-2Spike Glycoprotein, CoronavirusToll-Like Receptor 10A549 CellsCytokinesEpithelial CellsHumansImmunity, InnateLungTHP-1 CellsCoronavirus Nucleocapsid ProteinsCytokinesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2TLR10 protein, humanToll-Like Receptor 10COVID-19innate immunityinterferonsproinflammatory cytokinesSARS-CoV-2Toll-like receptor 10

Identifiers

PMID39902041
PMCPMC11788150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.